Cytokinetics Stock Today
| CYTK Stock | USD 50.25 1.15 2.34% |
Performance0 of 100
| Odds Of DistressOver 51
|
Cytokinetics is selling for 50.25 as of the 26th of November 2024. This is a 2.34 percent increase since the beginning of the trading day. The stock's last reported lowest price was 49.45. Cytokinetics has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Cytokinetics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of April 2004 | Category Healthcare | Classification Health Care |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. The company has 118.01 M outstanding shares of which 15.69 M shares are currently shorted by private and institutional investors with about 16.41 trading days to cover. More on Cytokinetics
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cytokinetics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Robert Blum | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Midcap 400, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCytokinetics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cytokinetics' financial leverage. It provides some insight into what part of Cytokinetics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cytokinetics (CYTK) is traded on NASDAQ Exchange in USA. It is located in 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 423 people. Cytokinetics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.79 B. Cytokinetics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 118.01 M outstanding shares of which 15.69 M shares are currently shorted by private and institutional investors with about 16.41 trading days to cover.
Cytokinetics currently holds about 586.03 M in cash with (414.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22.
Check Cytokinetics Probability Of Bankruptcy
Ownership AllocationThe majority of Cytokinetics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cytokinetics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cytokinetics. Please pay attention to any change in the institutional holdings of Cytokinetics as this could imply that something significant has changed or is about to change at the company.
Check Cytokinetics Ownership Details
Cytokinetics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 2.4 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.2 M | |
| Boxer Capital Llc | 2024-09-30 | 2.1 M | |
| Vestal Point Capital Lp | 2024-06-30 | 2.1 M | |
| Armistice Capital, Llc | 2024-09-30 | 1.9 M | |
| Alliancebernstein L.p. | 2024-06-30 | 1.9 M | |
| Pictet Asset Manangement Sa | 2024-06-30 | 1.8 M | |
| Partner Fund Management Lp | 2024-09-30 | 1.8 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.7 M | |
| Blackrock Inc | 2024-06-30 | 14.7 M | |
| Fmr Inc | 2024-09-30 | 12.1 M |
Cytokinetics Historical Income Statement
Cytokinetics Stock Against Markets
Cytokinetics Corporate Management
| John Esq | Associate VP | Profile | |
| Andrew Callos | Executive Officer | Profile | |
| Jeff Lotz | Vice Operations | Profile | |
| Steven Cook | Senior Operations | Profile | |
| Scott Jordan | Senior Strategy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.